Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibition Effects on Arterial Wall Inflammation in Patients With Elevated Lp(a)
2015-003731-35Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Evolocumab with Placebo (2 arms). Primary endpoint: Percent change from baseline in TBR within the MDS of the index vessel. Started Nov 2015; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on 2015-003731-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003731-35.